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superior patency afforded by aortobifemoral bypass is well docu-
mented in historical reports, and we sought to examine a different
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Dr Kelley Hodgkiss-Harlow (Tampa, Fla). I would like to
congratulate Dr. Huded and colleagues for a very well-written
paper. Thank you for providing it to me well in advance of the
meeting.
After reading your paper, which examined the utilization
and impact of adjunctive endovascular intervention for femoral-
femoral bypass, I have several questions. First, given that you
mention several times that the gold standard for inflow disease
in the setting of leg ischemia is aortobifemoral bypass, did you
include any cohort of patients who underwent either aortobi-
femoral, aortoiliac, or iliofemoral bypass in your surgical results
to compare patency?
Second, as you mentioned, other papers have compared pa-
tency of iliac stenting in the setting of TASC classification of the
lesions stented. Do you have any information on those patients in
your cohort in terms of TASC classification of their iliac lesions?
Third, what was the mechanism of failure in your iliac stent
group (ie, did procedures fail secondary to iliac stent failure or
occlusion, or were they more related to femoral-femoral bypass
issues or outflow issues)?
Lastly, since your group advocates a thorough investigation of
the iliac arteries prior to proceeding with femoral-femoral bypass,
were you able to see if this was performed in your cohort either
through angiographic or pressure measurements or computed
tomography imaging?
Dr Chetan P. Huded. Thank you, Dr. Hodgkiss-Harlow, for
your commentary. In regards to your first question about compar-
ison to direct anatomic bypass, such as aortobifemoral bypass, we
did not include a group of patients who underwent aortobifemoral
bypass or other direct anatomic bypass. We would submit that theroup of patients in whom presumably aortobifemoral bypass
ould not be a suitable procedure.
In regards to your second question about TASC classification,
e did not include anatomic information about donor iliac lesions
n our patient cohort.Wewould agree that anatomic characteristics
f the donor iliac artery could affect outcomes in our cohort, and it
ould certainly be an interesting variable to investigate. Unfortu-
ately, our data is limited in that regard. Moreover, the decision to
reat donor iliac occlusive disease was determined by the discretion
f the attending surgeon at the time of surgery, and we remain
imited in our ability to discern differences at the surgeon level.
In regards to your third question about mechanism of failure
n our iliac stent group, we believe that the mechanism of failure in
hese patients is likely multifactorial. Conceivably, it could repre-
ent residual untreated inflow iliac occlusive disease despite iliac
tent placement. Additionally, regarding the question of outflow,
e found no significant difference among the three groups that
ould explain diminished patency in the iliac stent group. How-
ver, a specific mechanism of failure for each patient was not
ecorded, so failure in the iliac stent group cannot be definitively
ttributed to any specific mechanism.
In regards to your fourth question about investigation of
nflow status at the time of fem-fem bypass, we remain limited in
ur ability to draw conclusions about inflow investigation, given
hat the use of pressure gradients or other mechanisms of inflow
nvestigation was left to the discretion of the attending surgeon at
he time of surgery, and there was no standardized utilization of
ny of the mechanisms you discussed. These would certainly be
nteresting interventions to investigate in the future.
Dr Ravi Veeraswamy (Atlanta, Ga). I guess I’m looking for
ome guidance here. Would you or your group advocate that I not
ut iliac stents in before fem-fem bypasses? What is the take-home
essage here? It’s hard for me to understand how you’re getting
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When we walk out of this room, how should we change our
practice based on these data?
DrHuded. Thank you for your question. We certainly wouldur study supports the conclusion that thorough investigation of
onor iliac occlusive disease at the time of fem-fem bypass when
erformed in conjunction with endovascular intervention is criti-
al. Ensuring that donor iliac occlusive disease is adequately treatednot suggest that iliac stenting at the time of fem-fem bypass is
inherently at fault for diminished patency rates in these patients.
prior to placement of a fem-fem bypass is the strongest clinical
conclusion that can be drawn from our data.
